A new trading day began on Friday, with Altimmune Inc (NASDAQ: ALT) stock price down -7.79% from the previous day of trading, before settling in for the closing price of $7.45. ALT’s price has ranged from $5.28 to $14.84 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 154.97% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 18.37%. With a float of $70.53 million, this company’s outstanding shares have now reached $71.12 million.
In an organization with 59 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -3857.69%, operating margin of -191365.38%, and the pretax margin is -199076.92%.
Altimmune Inc (ALT) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Altimmune Inc is 0.84%, while institutional ownership is 56.02%. The most recent insider transaction that took place on Aug 19 ’24, was worth 110,547. In this transaction Director of this company sold 16,011 shares at a rate of $6.90, taking the stock ownership to the 41,958 shares.
Altimmune Inc (ALT) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.34 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 18.37% per share during the next fiscal year.
Altimmune Inc (NASDAQ: ALT) Trading Performance Indicators
Here are Altimmune Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 16.87. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9772.60.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.55, a number that is poised to hit -0.34 in the next quarter and is forecasted to reach -1.24 in one year’s time.
Technical Analysis of Altimmune Inc (ALT)
Let’s dig in a bit further. During the last 5-days, its volume was 2.88 million. That was better than the volume of 2.8 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 34.56%. Additionally, its Average True Range was 0.60.
During the past 100 days, Altimmune Inc’s (ALT) raw stochastic average was set at 19.06%, which indicates a significant increase from 8.29% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.00% in the past 14 days, which was lower than the 82.54% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.03, while its 200-day Moving Average is $7.29. However, in the short run, Altimmune Inc’s stock first resistance to watch stands at $7.18. Second resistance stands at $7.50. The third major resistance level sits at $7.74. If the price goes on to break the first support level at $6.63, it is likely to go to the next support level at $6.39. The third support level lies at $6.07 if the price breaches the second support level.
Altimmune Inc (NASDAQ: ALT) Key Stats
With a market capitalization of 488.63 million, the company has a total of 71,125K Shares Outstanding. Currently, annual sales are 430 K while annual income is -88,450 K. The company’s previous quarter sales were 10 K while its latest quarter income was -22,850 K.
